Increasing evidence demonstrates that methylation of the promoter of CDKN2A, an important negative regulator of cell growth and proliferation [24], is involved in the tumorigenesis and progression of various tumors, including pancreatic [25], gastric [26], and prostate [27] cancers. This evidence concerns the gene CDKN2A and cancer.